Able VP joins Lachman

Executive Summary

Former Able Labs VP-Regulatory Affairs Joan Janulis joins the consulting firm as director of the regulatory group practice. Prior to joining Able in September 2004, Janulis served as VP-regulatory affairs for Alpharma from 2001 to 2004, where she helped secure the first approval for generic gabapentin capsules (Pfizer's Neurontin). Able voluntarily withdrew all of its products in May due to data integrity concerns and decided to sell its businesses and assets after FDA rejected the company's return-to-market plan in July (1"The Pink Sheet" Aug. 22, 2005, In Brief). The ANDAs involved in the data integrity issues were submitted prior to Janulis' employment at Able...